Summary
In order to learn more about the impact of lipoprotein metabolism on premature atherosclerosis, analysis not only of plasma lipids but also that of apolipoproteins have been performed in the past. Now we have reached a stage, where functional aspects become more and more prominent. Molecular biology has provided tools to routinely assay structural alterations of the proteins involved in the lipoprotein metabolism. In the near future, the DNA of patients might even be probed for abnormalities in the promotor region of apolipoprotein genes or their regulatory elements. Yet, without doubt, for clinical chemistry, the measurements of apolipoprotein concentrations will remain a key for classifying atherogenic lipoprotein constellations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fogelman AM, Haberland ME, Seager J, et al (1981) Factors regulating the activities of the LDL-receptor and the scavenger receptor on human monocyte-macrophages. J Lipid Res 22: 1131–1141
Frick MH, Elo O, Haapa K, et al (1987) Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317: 1237–1245
Goldstein JL, Brown MS (1982) Lipoprotein receptors: genetic defence against atherosclerosis. Clin Res 30: 417–426
Gordon T, Castelli WP, Hjortland MC, et al (1977) High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 62: 707–714
Hopkins PN, Williams RH (1981) A survey of 246 suggested coronary risk factors. Atherosclerosis 40: 1–52
Innerarity TL, Weissgerber KH, Arnold KS, et al (1987) Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 86: 6919–6923
Yound SG, Hubl ST, Smith RS, et al (1990) Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). J Clin Invest 85: 933–942
Kostner GM (1981) HDL-Cholesterin als Schutzfaktor gegen koronare Herzkrankheit. Internistische Welt 8: 311–320
Kostner GM (1984) Fettstoffwechsel and Atherosklerose. Z Allgemeinmedizin 26: 1087–1096
Kostner GM (1987) Diagnostik der Fettstoffwechselstörungen. Therapiewoche (Österr Ed) 3: 241–257
Kostner GM (1988) Pathobiochemie der Dyslipoproteinemien. Münch Med Wschr 130 /14: 251–255
Kostner GM (1990) The physiological role of LP(a). In: Scanu AM (ed) Lipoprotein(a). Academic Press, New York, pp 183–204
Utermann G (1987) Apolipoprotein E polymorphism in health and disease. Am Heart J 113: 433–440
NIH Publication (1984) The lipid research clinics coronary primary prevention trial. JAMA 251: 351–374
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag/Wien
About this chapter
Cite this chapter
Kostner, G.M. (1991). Biochemistry and pathophysiology of human plasma apolipoproteins. In: Rosseneu, M., Widhalm, K., Jarausch, J. (eds) Apolipoproteins in Lipid Disorders. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9148-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9148-4_1
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82273-9
Online ISBN: 978-3-7091-9148-4
eBook Packages: Springer Book Archive